Stocktoria
Dermata Therapeutics, Inc. DRMA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-08-13
Dermata Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $2.9M | $8.2M | $4.1M | $5.7M | $3.5M |
| SG&A expense | $4.8M | $4.3M | — | — | — |
| Operating income | -$7.8M | -$12.5M | -$8.0M | -$9.7M | -$7.9M |
| Interest expense | — | — | — | — | $45,613 |
| Income tax | — | $0 | $0 | $0 | $0 |
| Net income | -$7.6M | -$12.3M | -$7.8M | -$9.6M | -$7.9M |
| EPS (diluted) | $-8.16 | $-80.32 | $-39.99 | — | — |
| Operating cash flow | -$7.8M | -$11.2M | -$6.4M | -$8.8M | -$5.7M |
| Cash & equivalents | $7.5M | $3.2M | — | $6.2M | $10.8M |
| Total assets | $7.9M | $3.5M | $8.0M | $6.9M | $11.6M |
| Total liabilities | $1.6M | $2.0M | $1.6M | $922,634 | $1.5M |
| Shareholders' equity | $6.2M | $1.6M | $6.4M | $6.0M | $10.1M |
Source: SEC EDGAR filings · CIK 0001853816 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.